Lipocine Inc(LPCN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 6:18 AM ET (Korea 11/6 20:18)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.86 | Insider Own | 4.98% | Shs Outstand | 8.2M | Perf Week | 0.66% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 13.27% | Insider Trans | 10.07% | Shs Float | 7.8M | Perf Month | -30.45% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.36 | Inst Own | 36.21% | Short Float | 4.49% | Perf Quarter | -28.17% |
| Income | -0.01B | P/S | 8.03 | EPS this Y | 8.58% | Inst Trans | -7% | Short Ratio | 0.2 | Perf Half Y | -35.98% |
| Sales | 0.00B | P/B | 0.58 | EPS next 5Y | 17.47% | ROA | -55.89% | Short Interest | 0.35M | Perf YTD | -80.95% |
| Book/sh | 2.64 | P/C | 0.54 | EPS past 3/5Y | 5.11% 22.7% | ROE | -60.94% | 52W High | -87.63% ($12.37) | Perf Year | -40.23% |
| Cash/sh | 2.82 | P/FCF | - | Sales past 3/5Y | 58.12% - | ROIC | -54.45% | 52W Low | 12.5% ($1.36) | Perf 3Y | -40.7% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -121.27% | Gross Margin | 96.27% | Volatility(W/M) | 7.85% 7.76% | Perf 5Y | -91.96% |
| Dividend TTM | - | EV/Sales | -6.79 | Sales Y/Y TTM | -62.7% | Oper. Margin | -800.82% | ATR (14) | 0.13 | Perf 10Y | -97.07% |
| Dividend Ex-Date | - | Quick Ratio | 11.48 | EPS Q/Q | 22.54% | Profit Margin | -755.13% | RSI (14) | 40.44 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.48 | Sales Q/Q | -69.48% | SMA20 | -0.78% ($1.54) | Beta | 0.5 | Target Price | $5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/11/5 | SMA50 | -20.9% ($1.93) | Rel Volume | 0.23 | Prev Close | $1.44 |
| Employees | 14 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 77.46% 1335.8% | SMA200 | -59.02% ($3.73) | Avg Volume(3M) | 1.78M | Price | $1.53 |
| IPO | 2012/6/15 | Option/Short | No/Yes | Trades | 947 | Volume | 417,176 | Change | 6.25% |
💊 This is a U.S. small-cap biotech developing oral hormonal and nervous system therapies. The company earns royalty revenue from TLANDO, an FDA-approved treatment for male hypogonadism, while shifting its pipeline focus toward central nervous system (CNS) indications such as postpartum depression, liver cirrhosis, major depressive disorder, and epilepsy, making it an ultra-small, clinical-stage publicly traded company.
Over the past 1 year, on the lower side
88% below its 1-year high.
Traded less than usual. That is 23% of its average volume.
LPCN has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +8.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $803. Peers typically go for $877.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -92.0%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 36.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
DCOR US Core Equity 1 Portfolio ETF Class Shares <0.01% 
DFAC U.S. Core Equity 2 Portfolio-ETF Class Shares <0.01% 
DFAS U.S. Small Cap Portfolio-ETF Class Shares <0.01% 
DFSU Dimensional US Sustainability Core 1 ETF <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% It ranks #487 of 597 in the industry
Based on market cap of $13M.
FAQ
What kind of company is LPCN?
LPCN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LPCN?
The market cap of LPCN is approximately $13M, ranking 5,335 within its sector.
What is the 52-week high and low for LPCN?
LPCN has recorded a 52-week high of $12.37 and a low of $1.36.
